Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.03
SHPGF's Cash to Debt is ranked lower than
78% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. SHPGF: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
SHPGF' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 0.03

Equity to Asset 0.51
SHPGF's Equity to Asset is ranked higher than
62% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.24 vs. SHPGF: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
SHPGF' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.85
Current: 0.51

0.25
0.85
Interest Coverage 55.13
SHPGF's Interest Coverage is ranked higher than
69% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 55.13 )
Ranked among companies with meaningful Interest Coverage only.
SHPGF' s 10-Year Interest Coverage Range
Min: 2.96   Max: 55.13
Current: 55.13

2.96
55.13
F-Score: 5
Z-Score: 4.62
M-Score: -2.90
WACC vs ROIC
10.71%
24.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.38
SHPGF's Operating margin (%) is ranked higher than
95% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1702.36 vs. SHPGF: 30.38 )
Ranked among companies with meaningful Operating margin (%) only.
SHPGF' s 10-Year Operating margin (%) Range
Min: -56.61   Max: 35.13
Current: 30.38

-56.61
35.13
Net-margin (%) 58.55
SHPGF's Net-margin (%) is ranked higher than
98% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1412.53 vs. SHPGF: 58.55 )
Ranked among companies with meaningful Net-margin (%) only.
SHPGF' s 10-Year Net-margin (%) Range
Min: -59.59   Max: 56.55
Current: 58.55

-59.59
56.55
ROE (%) 50.20
SHPGF's ROE (%) is ranked higher than
98% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -61.96 vs. SHPGF: 50.20 )
Ranked among companies with meaningful ROE (%) only.
SHPGF' s 10-Year ROE (%) Range
Min: -90.18   Max: 49.38
Current: 50.2

-90.18
49.38
ROA (%) 27.71
SHPGF's ROA (%) is ranked higher than
98% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -39.06 vs. SHPGF: 27.71 )
Ranked among companies with meaningful ROA (%) only.
SHPGF' s 10-Year ROA (%) Range
Min: -37.5   Max: 31.55
Current: 27.71

-37.5
31.55
ROC (Joel Greenblatt) (%) 160.19
SHPGF's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1309.62 vs. SHPGF: 160.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPGF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -412.29   Max: 315.7
Current: 160.19

-412.29
315.7
Revenue Growth (3Y)(%) 12.40
SHPGF's Revenue Growth (3Y)(%) is ranked higher than
88% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 12.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPGF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.7   Max: 26.8
Current: 12.4

-0.7
26.8
EBITDA Growth (3Y)(%) 38.70
SHPGF's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 1055 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 38.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPGF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -1.4   Max: 38.7
Current: 38.7

-1.4
38.7
EPS Growth (3Y)(%) 56.30
SHPGF's EPS Growth (3Y)(%) is ranked higher than
98% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 56.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPGF' s 10-Year EPS Growth (3Y)(%) Range
Min: -7   Max: 62.8
Current: 56.3

-7
62.8
» SHPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SHPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.50
SHPGF's P/E(ttm) is ranked higher than
97% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 14.50 )
Ranked among companies with meaningful P/E(ttm) only.
SHPGF' s 10-Year P/E(ttm) Range
Min: 12.37   Max: 74.35
Current: 14.5

12.37
74.35
Forward P/E 15.36
SHPGF's Forward P/E is ranked higher than
91% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 15.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 15.00
SHPGF's PE(NRI) is ranked higher than
97% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 15.00 )
Ranked among companies with meaningful PE(NRI) only.
SHPGF' s 10-Year PE(NRI) Range
Min: 12.85   Max: 106.92
Current: 15

12.85
106.92
P/B 5.50
SHPGF's P/B is ranked lower than
57% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 5.50 )
Ranked among companies with meaningful P/B only.
SHPGF' s 10-Year P/B Range
Min: 2.01   Max: 14.23
Current: 5.5

2.01
14.23
P/S 8.20
SHPGF's P/S is ranked higher than
64% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 8.20 )
Ranked among companies with meaningful P/S only.
SHPGF' s 10-Year P/S Range
Min: 2.25   Max: 9.28
Current: 8.2

2.25
9.28
PFCF 13.50
SHPGF's PFCF is ranked higher than
97% of the 1061 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 13.50 )
Ranked among companies with meaningful PFCF only.
SHPGF' s 10-Year PFCF Range
Min: 9.58   Max: 42.14
Current: 13.5

9.58
42.14
POCF 11.42
SHPGF's POCF is ranked higher than
97% of the 1061 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 11.42 )
Ranked among companies with meaningful POCF only.
SHPGF' s 10-Year POCF Range
Min: 7.59   Max: 26.82
Current: 11.42

7.59
26.82
EV-to-EBIT 29.75
SHPGF's EV-to-EBIT is ranked higher than
91% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 29.75 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPGF' s 10-Year EV-to-EBIT Range
Min: -14.6   Max: 58.7
Current: 29.75

-14.6
58.7
PEG 0.54
SHPGF's PEG is ranked higher than
100% of the 1031 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 0.54 )
Ranked among companies with meaningful PEG only.
SHPGF' s 10-Year PEG Range
Min: 0.58   Max: 1.83
Current: 0.54

0.58
1.83
Shiller P/E 43.00
SHPGF's Shiller P/E is ranked higher than
93% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 43.00 )
Ranked among companies with meaningful Shiller P/E only.
SHPGF' s 10-Year Shiller P/E Range
Min: 30.76   Max: 143.7
Current: 43

30.76
143.7
Current Ratio 0.52
SHPGF's Current Ratio is ranked lower than
71% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 2.70 vs. SHPGF: 0.52 )
Ranked among companies with meaningful Current Ratio only.
SHPGF' s 10-Year Current Ratio Range
Min: 0.52   Max: 7.43
Current: 0.52

0.52
7.43
Quick Ratio 0.40
SHPGF's Quick Ratio is ranked lower than
71% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. SHPGF: 0.40 )
Ranked among companies with meaningful Quick Ratio only.
SHPGF' s 10-Year Quick Ratio Range
Min: 0.4   Max: 7.07
Current: 0.4

0.4
7.07
Days Inventory 215.68
SHPGF's Days Inventory is ranked higher than
71% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 215.68 )
Ranked among companies with meaningful Days Inventory only.
SHPGF' s 10-Year Days Inventory Range
Min: 113.08   Max: 270.35
Current: 215.68

113.08
270.35
Days Sales Outstanding 70.41
SHPGF's Days Sales Outstanding is ranked higher than
71% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 365.00 vs. SHPGF: 70.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPGF' s 10-Year Days Sales Outstanding Range
Min: 47.71   Max: 101.67
Current: 70.41

47.71
101.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.30
SHPGF's Dividend Yield is ranked higher than
82% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 0.30 )
Ranked among companies with meaningful Dividend Yield only.
SHPGF' s 10-Year Dividend Yield Range
Min: 0.16   Max: 0.7
Current: 0.3

0.16
0.7
Dividend Payout 0.04
SHPGF's Dividend Payout is ranked higher than
100% of the 1031 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 0.04 )
Ranked among companies with meaningful Dividend Payout only.
SHPGF' s 10-Year Dividend Payout Range
Min: 0.05   Max: 1.23
Current: 0.04

0.05
1.23
Dividend growth (3y) 16.00
SHPGF's Dividend growth (3y) is ranked higher than
99% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 16.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
SHPGF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 57.9
Current: 16

0
57.9
Yield on cost (5-Year) 0.64
SHPGF's Yield on cost (5-Year) is ranked higher than
84% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 0.64 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPGF' s 10-Year Yield on cost (5-Year) Range
Min: 0.34   Max: 1.5
Current: 0.64

0.34
1.5
Share Buyback Rate 0.20
SHPGF's Share Buyback Rate is ranked higher than
96% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
SHPGF' s 10-Year Share Buyback Rate Range
Min: 1.4   Max: -28.8
Current: 0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 42.00
SHPGF's Price/Tangible Book is ranked lower than
106% of the 1039 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 42.00 )
Ranked among companies with meaningful Price/Tangible Book only.
SHPGF' s 10-Year Price/Tangible Book Range
Min: 2.59   Max: 203.91
Current: 42

2.59
203.91
Price/DCF (Projected) 1.90
SHPGF's Price/DCF (Projected) is ranked higher than
95% of the 1042 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 1.90 )
Ranked among companies with meaningful Price/DCF (Projected) only.
SHPGF' s 10-Year Price/DCF (Projected) Range
Min: 1.12   Max: 2.65
Current: 1.9

1.12
2.65
Price/Median PS Value 2.10
SHPGF's Price/Median PS Value is ranked higher than
51% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. SHPGF: 2.10 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPGF' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 2.93
Current: 2.1

0.56
2.93
Price/Peter Lynch Fair Value 0.80
SHPGF's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1031 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 0.80 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPGF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 2.92
Current: 0.8

0.6
2.92
Price/Graham Number 5.50
SHPGF's Price/Graham Number is ranked higher than
83% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 5.50 )
Ranked among companies with meaningful Price/Graham Number only.
SHPGF' s 10-Year Price/Graham Number Range
Min: 1.15   Max: 19.65
Current: 5.5

1.15
19.65
Earnings Yield (Greenblatt) 3.40
SHPGF's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 3.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
SHPGF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.7   Max: 16
Current: 3.4

1.7
16
Forward Rate of Return (Yacktman) 27.15
SHPGF's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SHPGF: 27.15 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
SHPGF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.5   Max: 26.3
Current: 27.15

1.5
26.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:SHPG.USA, SHP.UK, S7E.Germany, SP2.Germany, SHPG N.Mexico,
Shire PLC was registered in Jersey on 28th January, 2008. It is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs. The Company unified its business during 2013 by integrating the operations of the Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM) business units into a simplified One Shire organization. The Company has four commercial units that focus exclusively on the commercial execution of its In-Line products in the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal (GI) and Internal Medicine. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the US, the EU and other territories.
» More Articles for OTCPK:SHPGF

Headlines

Articles On GuruFocus.com
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 
Shire Reports A Good Quarter Promoted By Drug Sales May 03 2015 
Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
Pioneer Investments Purchases Time Warner Cable, Kohl's in Q4 Feb 10 2015 
AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 

More From Other Websites
5 Stocks Set To Beat The FTSE 100: Aviva plc, Admiral Group plc, Shire PLC, United Utilities Group... May 26 2015
Calls bet on all-time highs in Shire May 26 2015
Could M&A Boost Pfizer More? Jefferies Thinks So May 22 2015
All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A May 21 2015
Can video game playing end ADHD drug reliance? May 21 2015
5 Big Pharma Stocks to Trade for Breakout Gains May 19 2015
Circassia £275m fundraising signals revival of UK biotech sector May 19 2015
John Paulson Continues To Bet On Health Care And TV May 17 2015
3 Shares Analysts Love: Lloyds Banking Group PLC, Shire PLC And Boohoo.Com PLC May 13 2015
4 Top Jefferies Growth Stock Calls for This Week May 11 2015
Which Pharma Stock Should You Buy: AstraZeneca plc, Shire PLC Or Hikma Pharmaceuticals Plc? May 06 2015
Shire Beats on Earnings & Revenue in Q1, View Reiterated - Analyst Blog May 04 2015
Shire (SHPG) Earnings Report: Q1 2015 Conference Call Transcript May 01 2015
Shire profits boosted by binge-eating drug Apr 30 2015
Shire Earnings Beat Estimates as ADHD, Rare Disease Drugs Surge Apr 30 2015
Shire delivers strong first-quarter earnings beat Apr 30 2015
4 Stocks Set To Post Stellar Returns: National Grid plc, Centamin PLC, Whitbread plc And Shire PLC Apr 28 2015
Inversion Deals Aren’t Dead, They’re Just More Low-Key: Real M&A Apr 25 2015
Why Are Shire PLC And Hikma Pharmaceuticals Plc Wiping The Floor With GlaxoSmithKline plc? Apr 24 2015
Shire Gets Dropped from AQR Capital’s Portfolio Apr 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK